Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, Brendan M. Weiss et al.|Clinical Cancer Research|2019Cited by 71
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, Simon J. Harrison et al.|Blood|2017Cited by 6